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Mertk is a therapeutic target in combination with radiation to promote adaptive immune 
tumor responses
Garth W. Tormoen1, Shelly Bambina2, Jason R. Baird2, Gwen Kramer2, Michael J. Gough2, Marka R. Crittenden2,3
1 - Department of Radiation Medicine, Oregon Health & Science University, Portland, OR USA
2 - Earl A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR USA
3 - The Oregon Clinic, Portland, OR USA
Background: Mertk is a member of the Tyro3-Axl-Mertk (TAM) family of 
receptors and regulates phagocytosis of dying cells by macrophages. 
Cancer cells killed by radiation therapy direct repolarization of 
macrophages into immune suppressive phenotypes. Mertk-/- mice 
grafted with immunogenic tumors have enhanced tumor control 
following ionizing radiation compared to wild type mice. Gas6 is the 
endogenous ligand for Mertk and its ability to signal through Mertk
requires a post-translational vitamin k-dependent modification that is 
inhibited by warfarin. 
Methods: Mertk-/- and WT mice were injected subcutaneously with 5E4 
CT26 cells (BALB/c) or 5E6 Panc02-SIY cells (C57BL/6) and allowed to 
grow to 5 mm before treatment with 250 µg anti-CD8α antibodies, 
warfarin (1.25 mg/L drinking water) and subjected to a single dose of 
ionizing radiation (12.5 Gy) followed by 250 µg of anti-OX40 or PBS I.P. 
1-day post-RT. Peripheral blood was collected 6 days after RT and 
evaluated by Flow Cytometry for SIY-pentamer+CD8+ T cells.
Results: Mertk-/- mice have increased survival following RT in CT26 
tumor models. CT26 tumor cure in Mertk-/- BALB/c mice was abrogated 
by depletion of CD8 T cells indicating that ligation of Mertk in tumor 
macrophages suppresses endogenous anti-tumor immunity following 
radiation therapy. Similarly, warfarin-treated mice had higher rates of 
tumor cure following radiation that was also abrogated by CD8 
depletion. In C57BL/6 mice, Mertk-/- alone does not affect responses to 
radiation therapy in the Panc02-SIY tumor model, but the combination 
of radiation therapy with anti-OX40 co-stimulation of T cell responses 
resulted in an increase in peripheral blood SIY+ CD8 T cells 5 days after 
treatment, and significantly improved survival compared to radiation 
alone.
Abstract
Tormoen, G.W., Crittenden, M.R., and Gough, M.J. The TAM family as a 
therapeutic target in combination with radiation therapy. Emerging Topics in Life 
Sciences. 2017; 1(5):493-500.
Model
b)
Figure 2. a) Mertk-/- mice on a BALB/c background were inoculated with 5*104
CT26 cells in the right flank. Tumors were allowed to grow to 5 mm before 
randomizing mice to intraperitoneal injections with vehicle (125 μL PBS) or α-
CD8 (250 μg). Tumors were then given a single fraction of stereotactic 
radiation to 12.5 Gy with repeat injections given weekly for a total of 3 doses. 
Mice were followed for tumor growth and survival. b) vehicle treated mice (   ) 
achieved tumor cure while αCD8-treated mice (   ) did not.
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Figure 4. a) BALB/c mice were inoculated with 50,000 CT26 cells in the right flank. Tumors were 
allowed to grow to 5 mm before randomizing mice to warfarin (1.25 mg/L drinking water) or no 
drug, then injections with vehicle (125 μL PBS) or αCD8 (250 μg). Tumors were then given a 
single fraction of stereotactic radiation to 12.5 Gy and repeat injections given weekly for a total of 
3 doses. Mice were followed for tumor growth and survival. b) warfarin treated mice (   ) exhibited 
similar tumor growth compared to control mice (   ) in the absence of radiation (i), but exhibited 
increased control of tumor growth compared to control animals when treated with RT (ii), that was 
abrogated with a CD8-depleting antibody (iii).
Warfarin enhances RT control in a CD8-
dependent manner
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Conclusions
• Mertk-/- mice show increased responsiveness to RT in 
immunogenic CT26 tumors
• Mertk-/- mice experience CT26 tumor cure after RT in a CD8-
dependent manner
• Poorly immunogenic pancreatic tumors do not have increased 
responses to RT in Mertk-/- mice
• In poorly immunogenic pancreatic tumors, the combination of RT 
and anti-OX40 significantly increased overall survival compared 
to RT alone, and resulted in increased numbers of long-term 
cures in Mertk-/- mice
• Warfarin alone at 1.25 mg/L in drinking water did not affect 
growth of CT26 tumor grafts, but enhanced RT control of tumor 
growth in a CD8-dependent manner similar to Mertk-/- mice
• Mertk expression in tumor macrophages prevents tumor cure by 
tumor antigen-specific T cells following radiation therapy. In 
poorly immunogenic tumors, combining RT with additional 
immune therapy is needed to increase T cell responses, but 
tumor cure is still limited by expression of Mertk.
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Figure 3. a) C57BL/6 mice were inoculated with 5*106 Panc02-SIY cells in the right flank. Tumors were allowed to grow for 12 days before treating with 5Gy 
stereotactic radiation on 3 consecutive days or no radiation and then injected intravascularly with CellTraceTM-labelled 2*106 CD8 T cells from 2C transgenic 
TCR mice that recognize SIY on MHCI. 4 days later, the tumor draining and contralateral lymph nodes were harvested, processed to single cell suspension and 
evaluated for CD8 T cell proliferation by flow cytometry. b) Mertk-/- mice on BL/6 background or C57Bl/6 wild-type mice were inoculated with 5*106 Panc02-SIY 
cells in the right flank. Tumors were allowed to grow to 5mm diameter before treating with a single dose of stereotactic radiation to 12.5 Gy or no radiation. One 
day after RT, mice were given intraperitoneal injections with αCD8 (250 μg) or vehicle (125 μL) and followed for tumor growth and survival (ii). 5 days after 
treatment, peripheral blood was drawn and evaluated by flow cytometry for CD8+SIY+ T cells (iii).
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Improved survival in Mertk-/-
mice treated with RT
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Figure 1. a) Mertk wild-type and knock-out mice on a BALB/c background 
were inoculated with 5*104 CT26 cells in the right flank. b)Tumors were 
allowed to grow to 5 mm before randomizing a single fraction of stereotactic 
radiation (0, 3,6 or 12.5 Gy). c)Mice were followed for survival. 
